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Abstract Sirtuins (SIRT), first described as nicotinamide
adenine dinucleotide (NAD?)-dependent type III histone
deacetylases, are produced by cells to support in the defense
against chronic stress conditions such as metabolic syn-
dromes, neurodegeneration, and cancer. SIRT-3 is one of the
most studied members of the mitochondrial sirtuins family.
In particular, its involvement in metabolic diseases and its
dual role in cancer have been described. In the present
review, based on the evidence of SIRT-3 involvement in
metabolic dysfunctions, we aimed to provide an insight into
the multifaceted role of SIRT-3 in many solid and hemato-
logical tumors with a particular focus on hepatocellular
carcinoma (HCC). SIRT-3 regulatory effect and involvement
in metabolism dysfunctions may have strong implications in
HCC development and treatment. Research literature widely
reports the relationship between metabolic disorders and
HCC development. This evidence suggests a putative bridge
role of SIRT-3 between metabolic diseases and HCC.
However, further studies are necessary to demonstrate such
interconnection.
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Abbreviations
SIRT Sirtuin
SOD2 Superoxide dismutase 2
HCC Hepatocellular carcinoma
HBV Hepatitis B virus
HCV Hepatitis C virus
AIH Autoimmune hepatitis
PBC Primary biliary cholangitis
NASH Nonalcoholic steatohepatitis
DM2 Type 2 diabetes mellitus
NAFLD Nonalcoholic fatty liver disease
MnSOD Superoxide dismutase 2
OSCC Oral squamous cell carcinoma
NMNAT2 Nicotinamide mononucleotide
adenylyltransferase 2
GC Gastric cancer
MIAM 2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-
yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic
acid methyl ester
Introduction
Sirtuins (SIRT) were first described as nicotinamide ade-
nine dinucleotide (NAD?)-dependent type III histone
deacetylases [1]. In mammals, the sirtuin family is com-
posed of seven members (SIRT-1–SIRT-7), which differ in
tissue distribution, subcellular localization, enzymatic
activity, and target proteins. SIRT-3 is the most studied
member of the mitochondrial sirtuin family. It localizes
mainly in the mitochondria, binding and deacetylating
several enzymes involved in metabolism such as superox-
ide dismutase 2 (SOD2) and catalase [2]. The increased
expression of these antioxidant proteins is related to SIRT-
3 overexpression [3]. This protein is characterized by a
conserved enzymatic core containing both the catalytic and
NAD? binding domains [2].
A crucial aspect concerns the role of SIRT-3 in meta-
bolism and cancer. Advancements of knowledge in this
new field of research will allow for a better understanding
of the mechanisms by which SIRT-3 can reprogram cel-
lular metabolism and regulate different cancer processes.
Interestingly, growing evidence has proven a role for
SIRT-3 in some important hallmarks of cancer (Fig. 1).
SIRT-3 regulates cell survival, death, and metabolic path-
ways, maintaining the balance between health and disease
[4].
Several studies have described an involvement of the
enzyme in metabolic disorders [5–7].
The relationship between its role in metabolic diseases
and in the development of hepatocellular carcinoma (HCC)
could be of particular interest.
HCC is the sixth most frequent tumor in men and the
third cause of cancer-related death worldwide. The
majority of HCCs in humans are superimposed on chronic
liver disease, as a result of hepatitis B and C virus (HBV
and HCV) infection, excessive alcohol consumption,
autoimmune hepatitis (AIH), primary biliary cholangitis
(PBC), and nonalcoholic steatohepatitis (NASH) [8].
HCC incidence is significantly increasing in Western
countries due to new metabolic-associated risk factors,
including obesity, diabetes, and other causes of nonalco-
holic fatty liver disease [9, 10].
This article reviews the experimental evidence of SIRT-
3 involvement in metabolism and cancer, highlighting the
interplay between metabolic dysfunctions and its tumor
suppressor role in HCC.
SIRT-3 in the Regulation of Cell Metabolism
SIRT-3 is an important player in regulating mitochondrial
functions such as metabolism and response to oxidative
stress [11–17].
The function of SIRT-3 is connected to the metabolic
state of the cell, since its enzymatic activity is controlled by
the cellular NAD?/NADH ratio. In this respect, NAD?
serves as an activator, while NADH and nicotinamide as
feedback inhibitors [18, 19].
Certain cellular stressors or a low energy state in the cell
is responsible for NAD?/NADH ratio increase, nicoti-
namide level decrease, and SIRT-3 activation [18, 19].
The SIRT-3 knockout mouse model has been used to
clarify the physiological role of the enzyme in metabolism.
Hebert et al. [20] described a loss of SIRT-3, using mass
spectrometry during caloric restriction, suggesting that
SIRT-3 is an important regulator in caloric restriction
adaptation.
By contrast, an increased expression of the enzyme has
been observed during dietary restriction [13, 15, 21]. For
example in the study published by Hirschey et al., it has been
reported that SIRT-3 knockout mice showed a reduced fat
oxidation in different tissues, fatty liver and decrease in
hepatic ATP production, glycaemia, and cold tolerance [21].
Metformin, a biguanide drug commonly used in patients
with type 2 diabetes mellitus (DM2), was observed to have
attenuated in vivo mitochondrial expression of SIRT-3 in
primary hepatocytes: This was associated with an enhanced
acetylation of several mitochondrial proteins, suggesting an
involvement of metformin in the regulation of energy
metabolism in liver and a potential therapeutic effect of
this compound [22].
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SIRT-3 and Metabolic Disorders
The above-mentioned studies suggest SIRT-3 as a
promising therapeutic target against the dysfunctions that
affect the mitochondrial metabolism [5–7].
Hirschey et al. [23] demonstrated how the reduction in
SIRT-3 enzymatic activity and a high-fat diet feeding are
associated with accelerated development of obesity, insulin
resistance, and NASH. In this study, SIRT-3-deficient
mice, under stress conditions, demonstrated that the lack of
SIRT-3-mediated deacetylation of its target enzymes was
insufficient for supporting the metabolic derangement
caused by obesity and NASH. The authors also identified a
functional single nucleotide polymorphism of the human
SIRT-3 gene and associated with the metabolic syndrome
development [23].
This study indicates that SIRT-3 plays a key role in
protecting against mitochondrial oxidative stress through
the regulation of the acetylation status of its target proteins.
The importance of SIRT-3 in regulating oxidative stress
and impacting the pathogenesis of metabolic disorders such
as NASH was also confirmed by He et al. [24] and
demonstrated how manipulation of the expression or
activity of SIRT-3 may represent a novel approach to
manage NASH. According to this view, SIRT-3 could
represent a potential therapeutic target in treating meta-
bolic disorders.
In our opinion, this represents one important field of
research to develop new therapeutic strategies for NASH
management that, up to date, provides the lifestyle changes
and an increased physical activity.
HCC and Metabolic Disorders
In the last years, DM2, metabolic syndrome, and NASH
have been described as important risk factors for HCC
development [25]. A 2.6% yearly incidence of HCC has
been reported in patients with NASH-related cirrhosis [25].
Higher prevalence of obesity and diabetes mellitus has
been related to increased nonalcoholic fatty liver disease
(NAFLD), currently known as one of the causes of chronic
liver disease worldwide [26, 27].
Considering the relationship between metabolic disor-
ders and HCC development, the involvement of SIRT-3 in
metabolic dysfunctions may have strong implications in
HCC development and treatment. However, to date, there
are no evidences on the interconnection among SIRT-3,
metabolic disorders, and HCC. Further studies are neces-
sary to demonstrate a putative bridge role of the enzyme.
Some retrospective studies and meta-analysis, per-
formed on patients with DM2, suggested that metformin
prevented HCC development [28–30], especially in those
with chronic liver disease [31], while the use of sulfony-
lureas or insulin was associated with an increased risk of
HCC [30]. Conversely, no significant association between
thiazolidinediones use and HCC has been observed [30].
Based on meta-analysis results, diabetic patients at high
risk for HCC development should be treated with
metformin.
Dual Role of SIRT-3 in Cancer
The role of SIRT-3 in cancer is complex and controversial.
Advancements of knowledge in this new field of research
will allow for a better understanding of the mechanisms by
which SIRT-3 can regulate different cancer processes.
The link among mitochondrial functions, metabolism,
and cancer has been well reported in different solid tumors,
where SIRT-3 regulates glycolytic and antioxidant genes
expression, leading to a reduction in ROS production [17].
The scientific evidences about the role of SIRT-3 in cancer
metabolism are reported in Table 1.
Fig. 1 SIRT-3 and the
hallmarks of cancer. SIRT-3 can
link to four hallmarks of cancer
such as genomic instability,
sustaining proliferative
signaling, dysregulating
energetic status, tumor-
promoting inflammation
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Tao et al. [32] observed a direct link between SIRT-3
and genomic stability. Indeed, SIRT-3 seems to regulate
ROS production through manganese-containing superoxide
dismutase 2 (MnSOD) and SOD modulation, promoting
mutagenesis and genomic instability.
A study reported that SIRT-3 mediates metabolic
reprogramming, destabilizing HIF-1a, and regulating gly-
colytic gene expression [33]. According to these observa-
tions [33], ROS production, glycolysis, and proliferation
are inhibited by SIRT-3 overexpression, under hypoxic
conditions, leading to HIF-1a stabilization and transcrip-
tional activation [34, 35].
Different studies described a dual role of SIRT-3 in
different solid and hematological tumors (Fig. 2).
In oral squamous cell carcinoma (OSCC), SIRT-3
resulted more expressed than normal oral tissues and its
down-regulation inhibited OSCC cell growth and prolif-
eration in vitro, indicating a tumor promoter role [36].
Lai et al. [37] nonetheless reported that levels of SIRT-3
and other sirtuins were significantly more down-regulated
in tumor tissues than in normal tissues from patients
affected by head and neck squamous cell carcinoma.
Moreover, SIRT genes expression was shown to be more
down-regulated in advanced than in early stages, causing
the neoplastic disease to develop a more aggressive
phenotype.
The pro-proliferative function of SIRT-3 has been also
demonstrated in melanoma [38]. Indeed, SIRT-3 resulted
overexpressed in a range of human melanoma cell lines
with a different gene mutational status compared to normal
primary melanocytes, suggesting the enzyme as a promis-
ing target for the treatment of this disease.
A recent study suggested that SIRT-3 plays a tumor-
progressive role in renal carcinoma cells via glutamine-
dependent oxidation, leading to reduced mitochondrial
functions [39].
In breast cancer, the role of SIRT-3 remains
contradictory.
Furthermore, Zhang et al. [40] showed that SIRT-3
expression levels increased in tamoxifen-resistant breast
cancer cells and that SIRT-3 silencing sensitized these cells
to tamoxifen, inducing apoptosis. On the contrary, another
study described SIRT-3 as a tumor suppressor in human
breast cancer, in part by regulating cellular metabolism
through HIF-1a destabilization [33]. HIF-1a plays an
important role in the Warburg effect in regulating several
glycolytic genes and increasing anaerobic catabolism. This
process supports the rapid proliferation of tumor cells.
Finley et al. [33] demonstrated that a loss of SIRT-3 sta-
bilized HIF-1a and increased glycolysis, whereas its
overexpression repressed the Warburg effect in human
breast cancer cell lines. This evidence suggests that the
regulation of tumor cell metabolism by SIRT-3 could
provide new ways of therapeutic approach.
Recently, it has been described a SIRT-3 up-regulation
in human ovarian cancer cells after treatment with Bcl-2
inhibitors that interrupted glucose metabolism and induced
apoptosis. This study suggests a tumor suppressor role of
SIRT-3 in this solid tumor [41].
Low levels of SIRT-3 have been reported to induce energy
metabolism-related apoptosis in non-small cell lung cancer
cells through deacetylation of nicotinamide mononucleotide
adenylyltransferase 2 (NMNAT2) and NAD ? synthesis
activity [42].
As shown by Xiao et al. [43], SIRT-3 expression
appeared more down-regulated in human lung adenocar-
cinoma tissue than in the adjacent normal tissue. This study
demonstrated that SIRT-3 overexpression-induced apop-
tosis-inducing factor (AIF) translocation to the nucleus up-
regulated p53 and p21 protein levels and reduced intra-
cellular ROS levels, exerting a pro-apoptotic function in
this tumor.
Table 1 SIRT-3 in cancer metabolism
SIRT-3 functions Key mechanism Research team
Mutagenesis and genomic instability promoter MnSOD and SOD modulation Tao et al. [32]
Tumor suppressor HIF-1a destabilization and glycolytic genes expression regulation Finley et al. [33]
Schumacker [34]
Tumor promoter Glutamine-dependent oxidation Choi et al. [39]
Tumor suppressor Glucose metabolism interruption via Bcl-2 inhibition Xiang et al. [41]
Tumor promoter NMNAT2 deacetylation and NAD ? synthesis activity regulation Li et al. [42]
Tumor suppressor ROS levels decrease via p53 and p21 up-regulation Xiao et al. [43]
Tumor suppressor ROS levels decrease and HIF-1a destabilization Yang et al. [46]
Tumor suppressor IDH2 and SOD deacetylation Yu et al. [49]
Tumor suppressor ROS levels decrease via SOD2 activation Wang et al. [54]
SIRT-3 functions, key molecular mechanisms, and research team
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In line with this evidence, it has been reported that the
enzyme promoted apoptosis, down-regulating Bcl-2 and
JNK2 in HCT116 human epithelial colon carcinoma cells
[44].
On the contrary, Liu et al. [45] demonstrated that a high
SIRT-3 expression significantly correlated with high tumor
grades, lymph nodes involvement, and poor prognosis in
colon cancer patients.
Notably, SIRT-3 expression levels were inversely cor-
related with tumor infiltration and differentiation of gastric
cancer (GC). SIRT-3 silencing could increase the expres-
sion of HIF-1a, suggesting its tumor suppressor role in GC
[46].
In line with the results obtained by Yang et al. [46], it
has been demonstrated that mRNA and protein levels of
SIRT-3 were significantly reduced in human gastric cancer
tissues and cell lines [47]. Moreover, Notch-1 overex-
pression inhibited the suppressor function of the enzyme on
tumor cells proliferation, suggesting SIRT-3 as a novel
therapeutic target in the gastric cancer treatment.
To date, few studies on the role of SIRT-3 in hemato-
logical malignancies have described the enzyme as tumor
suppressor.
Marfe et al. [48] observed that the kaempferol treatment
induced the inactivation of Akt signaling, the activation of
caspase-3, followed by an increase in Bax and SIRT-3 and
a decrease in Bcl-2 in chronic myelogenous leukemia K562
and promyelocytic human leukemia U937 cells.
Other findings have shown a SIRT-3 reduction in
malignant B cell lines and primary samples obtained from
chronic lymphocytic leukemia patients compared to con-
trols from healthy donors. Decreased expression of the
enzyme also correlated with hyperacetylation of IDH2 and
SOD2 and higher ROS levels in these patients [49]. These
results suggest that the activation of SIRT-3 pathway may
represent a novel therapeutic approach for treating B cell
malignancies.
As reported above, the role of SIRT-3 in cancer still
remains ambiguous due to its possible function as an
oncogene or a tumor suppressor, depending on the cancer
cells and the pathways in which it is involved (Fig. 3).
The controversy regarding its dual role in cancer high-
lights the importance of investigating this research field.
The knowledge of molecular mechanisms in several cancer
types will clarify the oncogenic and tumor-suppressive
function of SIRT-3 and help in developing a promising
therapeutic strategy. Currently, in the early stages of clin-
ical trials, SIRT-3 activators such as resveratrol have been
tested for safety and cancer treatment [50].
The Tumor Suppressor Role of SIRT-3 in HCC
Mitochondria are the main site of ROS production, which
has been reported as oncogenic factors and again are
important site for apoptosis pathways. All of which seems
to play a relevant role in hepatocarcinogenesis [51]. It has
been demonstrated that ROS, produced by mitochondria,
contributed to HCC progression and metastasis, inducing
DNA damage or alteration of mitochondrial pathways
[52, 53].
Several studies reported an involvement of SIRT-3 in
tumor progression through HIF-1a and mitochondrial ROS
production inhibition [33, 34].
SIRT-3 reduces ROS levels via SOD2, a major mito-
chondrial antioxidant enzyme that promotes oxidative
stress resistance [4, 32].
Wang et al. [54] showed that the expression of SOD2
positively correlated with that of SIRT-3 in HCC cases,
supporting the concept that SIRT-3 may reduce ROS pro-
duction through the activation of SOD2. In agreement with
the relationship between SOD2 and SIRT-3, several reports
also showed a strong correlation between SOD2 reduced
expression levels and HCC progression [55, 56]. Taken
together, these data underlined the clinical relevance of
SIRT-3 and its targets in HCC.
Several intracellular proteins are involved in the mito-
chondrial regulation of apoptosis, in particular the Bcl-2
protein family, which includes pro- and anti-apoptotic
Fig. 2 Dual role of SIRT-3 in solid and hematological tumors
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members [57]. Among them, SIRT-3 is one of the main
actors in the mitochondrial apoptotic pathway in HCC
cells. SIRT-3 has been described as tumor suppressor in
this neoplasm.
Song et al. [58] showed that GSK-3b localized in the
mitochondria, where it interacted with SIRT-3, inducing
Bax activation and translocation to the mitochondria. The
same study revealed that overexpressed SIRT-3 up-regu-
lated GSK-3b expression and activity, underlining its role
as a tumor suppressor in HCC cells.
In line with that, mRNA and protein levels of SIRT-3
were lower in HCC tissue than in the peritumoral tissue and
the reduced expression of the enzyme correlated with
tumor de-differentiation, advanced staging, serum alpha-
fetoprotein level, tumor multiplicity, and higher recurrence
[59].
Moreover, Wang et al. [54] confirmed that SIRT-3
mRNA and protein levels were more down-regulated in
HCC than normal livers and this reduction was signifi-
cantly associated with tumor grade and size, highlighting
the tumor suppressor role of the enzyme. The study also
indicated that SIRT-3 may be considered a biomarker of
recurrence after hepatectomy, in particular in BCLC stage
A or no vascular invasion patient group.
It was found that the enzyme decreases hepatitis B virus
x protein (HBx)-induced ROS production after viral
infection [60]. This role in the regulation of oxidative stress
after infection suggests that SIRT-3 could act in the control
of fulminant hepatitis caused by viruses.
Furthermore, the overexpression of SIRT-3 repressed
the extracellular signal-regulated kinase 1/2 pathway,
partly blocked the activation of Akt, and down-regulated
Mdm2, preventing p53 degradation with anti-tumor effect
(Fig. 4) [61].
Even if SIRT-3 has been described as tumor suppressor
in HCC, its role in drug sensitivity of liver cancer cells
remains unclear.
Only a recent study highlighted a decreased SIRT-3
expression after the treatment with doxorubicin, cisplatin,
and sorafenib in different HCC cell lines, suggesting a
regulatory role of the enzyme in the drug sensitivity of
HCC cells [62].
Another study demonstrated that fusaric acid-induced
decreased mRNA and protein expression of SIRT-3 may be
a putative mechanism of action in promoting cytotoxicity
in HepG2 cell line [63].
Li et al. [64] demonstrated that HCC cells with high
SIRT-3 expression levels were more sensitive to 2-[1-(3-
Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-
1H-indol-3-yl}-acetic acid methyl ester (MIAM) than
control cells, suggesting that MIAM inhibited HCC
growth, due to SIRT-3 increase.
The results of another research reported that MIAM more
strongly inhibited the growth of HCC in the resistant vari-
ants of Bel-7402 cell line through the activation of the
NADPH oxidase 4 (NOX4)/p22, SIRT-3/SOD2 and SIRT-3/
p53/p21 pathways [65]. This evidence suggests that MIAM
could be developed as a potential treatment agent for HCC.
Conclusion
The role of SIRT-3 in cancer remains controversial. The
advancements of the knowledge in this new research field
will allow for a better understanding of the mechanisms by
which SIRT-3 can regulate different cancer processes.
Moreover, SIRT-3 has been recognized as an important
regulator of mitochondrial integrity. Its regulatory effects
Fig. 3 SIRT-3 plays an either
oncogenic or tumor-suppressive
role in cancer, regulating
several molecular effectors
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and involvement in metabolic diseases may have strong
implications in HCC development and treatment. For this
reason, the discovery of selective SIRT-3 activators could
have an important role in giving new therapeutic alterna-
tives. However, many questions on the role of SIRT-3 and
its potential application in HCC remain unanswered, con-
sidering the complex background of this disease. We
hypothesize that the effects of SIRT-3 activators could be
different in HCC patients at distinct etiology. Up to date,
there are no evidences on the interconnection among SIRT-
3, metabolic liver disorders or viral infections, and HCC.
Further studies are necessary to demonstrate a putative
bridge role of the enzyme.
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